Menu
Professional & Student Poster Presentations
Student
- M-01: Does Medication Therapy Management by Pharmacists Lower Cost-related Medication Nonadherence in Medicare Beneficiaries
- M-02: Study of Cerebrospinal Fluid Adenosine Deaminase for Differential Diagnosis of Tuberculous and Non-tuberculous Meningitis
- M-03: To Evaluate Efficacy of Aerobic Exercise as an Addition to the Existing Treatment in Primary Open Angle Glaucoma Patients
- M-04: Characterizing a Good Drug Review
- M-05: Public Knowledge and Perception of Clinical Research in Mumbai
- M-06: Analysis of FDA Guidance of Off – Label Medical Product Advertising
- M-07: Efficacy of Unapproved Drugs in Compassionate use in Comparison With Clinical Trial Results: A Systematic Review
- M-08: Postmarketing Drug Dosage Changes of 413 FDA-approved New Molecular Entities, 2000-2014
- M-10: Trend Analysis of the Top 20 Most Frequently Issued Form 483’s by the Food and Drug Association (FDA) From 2006 to 2016.
- M-11: Pharmacovigilance Summary Reports: Global Challenges with Harmonization of Canadian, American and European Perspectives
- M-12: Prevalence and characteristics of electronic cigarette use among individuals with COPD in the United States
- M-13: Development Challenges for Maternal and Child Health Care Institutions in China: A Qualitative Study in Chengdu
- M-14: Assessing Consistency of Subgroup Specific Treatment Effects in Clinical Trials with Binary Endpoints
- M-15: Clinical Trials of Medical Devices: Decisional Trees for Optimizing the Choice of Study Design
- M-16: Protective Effect of Juice, Ether and Ethyl Acetate Extracts of Benincasa Hispida Fruit in PTZ Induced Seizures in Zebra Fish
- M-17: Therapeutic Cancer Vaccines: Overview of Phase 3 Clinical Trials
- M-18: Cost Utility Analysis of Fixed Versus Free Dose Antihypertensiv Combinations: Evidence From the 2014 MEPS
- M-19: The Rising Cost of Generic Drugs (2013 - 2016): A Review
- M-20: Quality and Report of Subgroup Analysis in Randomized Controlled Trials
- M-21: Can Laughter Therapy be Used as an Add-on Therapy Alongwith Anti-Anxiety and Anti-Depression Drugs? An Interventional Research.
Professional
- T-01: An Innovation: Automated Statistical Programming with CDISC Analysis Results Metadata
- T-02: Collaborative Efforts Toward Full-scale Utilization of Medical Information Database Network (MID-NET®)
- T-03: Diabetes Defender – Changing At-Risk Population Behavior Using Analytics
- T-04: Incorporating HIT Within REMS Programs to Address REMS Stakeholder Burden
- T-06: Fresh Insights on Health: Lessons Learned from Mobile Game Use to Train Attention and Planning in Teens
- T-07: An Analysis of Medical Call Center Response Among Consumer Healthcare Companies in the United States
- T-08: A Quantitative Analysis to Determine Whether Clinical Trials are Proportionately Distributed Across Cancer Indications
- T-10: Patient Perceptions & Utilization of Patient Information Leaflets (PILs)
- T-11: Pragmatic Randomized Clinical Trials: Key Insights from Investigators in COPD and Diabetes
- T-12: Asthma and COPD Patients Consider Training Necessary in Clinical Trials, Preferring Interactive Electronic Training
- T-13: Exploring Subjects’ Opinions About Option to Skip Items in ePRO: An Online Survey Study
- T-14: Engaging Patients in the Consent Process Through Virtual Reality
- T-16: Patients With Gastrointestinal Disorders Prefer Electronic and Interactive Training When Participating in a Clinical Trial
- T-17: An Evaluation of Global Over-The-Counter Medical Device Labeling Regulations
- T-18: Analysis of US Food and Drug Administration (FDA)’s Process for Evaluating Bulk Drug Substances for Use in Compounding
- T-19: Assessing Trends in Clinical Data Packages for Orphan Indications
- T-20: Assessment of Patient Perceptions Towards Direct-to-Consumer Advertising
- T-21: Benchmarking Regulatory Processes in Emerging Markets Through Key Performance Indicators
- T-22: Current Trends in Global Regulations of Human Cells and Tissue Products
- T-23: Delegation of Responsibilities-Guidance in Response to FDA Audits
- T-24: Evaluating the Approval Pathway of Biosimilars in the U.S. Market
- T-25: Impact of US Breakthrough Therapy Designation on Approval Timelines of Drugs and Biologics in the EU
- T-26: Case Study: Computing Complexity Scores to Identify Patients of Interest from Inspire.com Forums for Safety and Beyond
- T-27: Key Aspects and Lessons Learnt for Maintaining a Robust and Efficient Global 24/7 Medical Emergency Coverage Service
- T-28: Safety Evaluation of Bulk Drug Substances for Use in Compounding
- T-29: Term Indexing Technology to Support the Feasibility Assessment of a Network Meta-Analysis to Support Benefit-Risk Assessment
- T-30: Trends in Response Rate for Recurrent REMS Surveys
- T-31: What’s in a Name? Distinguishable Naming and its Role in PV for Biosimilars: What do Australian Physicians Think?
- T-32: Development of a Cognitive Assessment Score Transformation (CAST) System to Support the TOMMORROW Study
- T-33: Impact of Strategic Partnerships With Clinical Trial Sites and Role of Alliance Managers in Execution
- T-34: Implement Refuse to File (RTF) Mechanism on Drug Review Process to Enhance the Quality and Submission of Application Submissi
- T-35: Improving Probability of Success – Better Project Outcomes through Scale Appropriate Stage Gating
- T-36: Precision Enrollment in Oncology: Accelerating Start-up and Recruitment
- T-37: Remote Site Management - A Rising Star in Our Clinical Research Ecosystem
- T-38: So You Want to Redesign a Website Supporting a Complex, Global, Multi-Stakeholder Clinical Research Enterprise …Now What?
- W-01: Developing Research Partnerships with Health Networks for Real World Evidence Generation
- W-02: Healthcare Link Project in Japan: Development of a New Seamless Data Stream from EHR to EDC System Using SS-MIX2 Storages
- W-03: Searching the Registries for Trial Submission QA and Competitor Intelligence - Comparing ClinicalTrials.gov and EudraCT
- W-04: Treatment Comparisons of Timed Tests in Neurology
- W-05: What's the Best Download Format from NIH ClinicalTrials.gov? - Comparing Data Availability in Different Export Options
- W-05.1: Do the Variables that Predict the Number of Cancer Clinical Trials in the United States Differ by Sponsor type?
- W-06: Preferred Method for Answering Questions about Suicidal Ideation and Behaviors (SIB) in Patients at Greater Risk for SIB
- W-07: REMS Call Center Survey: REMS Stakeholder Perceptions on Call Center Performance and REMS Program Administrative Burden
- W-08: The Benefits of Knowing Patient Preferences in the Clinical Trial Continuum
- W-09: The Development and Launch of a Unique Retention Focused Patient Centric Online Community for the TOMMORROW Study
- W-10: Use of Digital Mobile App to Keep Clinical Trial Participants Engaged - Driving innovation in early clinical trials at Roche
- W-11: Faster Approvals? Trends in the Use of FDA’s Expedited Approval Programs for Oncology Medications
- W-12: FDA Inspections in Japan: A Comparison with PMDA inspections
- W-13: Influence of Orphan Drug Designation, Breakthrough Therapy Designation, and Advisory Committees on NDA/BLA Review Timelines
- W-14: IRB Submissions and Approvals in Japan: A review
- W-15: Pediatric Development of Molecularly Targeted Oncology Drugs
- W-16: Precepting Pharmacy Students in a Regulatory Affairs Rotation Program
- W-17: Racial Effect Analysis in Supporting Drug Application for ST-101, A Fixed Dose Combination of Olmesartan and Rosuvastatin
- W-18: SDTM/ADaM Compliant or Sufficient Submission for Legacy Studies
- W-19: Expanded Access Programs (EAP): A Look at 2015-2016 Orphan Designated New Molecular Entities
- W-20: Honesty in Reporting Suicidal Ideations and Behaviors in Alzheimer’s Disease, Mild Cognitive Impairment, and Other Dementias
- W-21: Prevalent Issue with Patient Selection in Oncology Clinical Trials
- W-22: Recent Pharmacokinetic Studies in Patients with Hepatic Function Impairment at a Phase 1 Clinical Research Site in Japan
- W-23: Representation of Adult Obese Subjects in Pivotal Clinical Trials for Products approved by FDA in 2015
- W-24: Role of the Pharmacist in Global Health: A Cross-sectional Survey of Pharmaceutical Industry PharmD Fellows
- W-25: More of What Works: Detection of Informative Sites During the Conduct of Clinical Trials Using Machine Learning
- W-26: Statistical Issues in Human Drug Abuse Study – Two Different Types of Studies
- W-27: The Balance between Compassion, Cost, & Commercialization in Expanded Access Programs: Managing Complexities
- W-28: Two Independent Phase 3 Studies Did Not Meet Pre-specified Endpoints, What's Next?
- W-29: Quality of Decision-making Process in the Development, Review and Reimbursement of Medicines; Its Importance and Implication
- W-30: How a Centralized Feasibility Service Attracts Sponsors and Contract Research Organizations to Malaysia
- W-31: Retrospective Chart Review Studies: Opportunities and Challenges to Post-Market Evidence Generation
- W-32: A U.S. REMS Quality Strategy: A Comprehensive Approach
- W-33: Promoting a Data-Driven Simulation Model to Enhance Quality in Rare Disease Clinical Trials
- W-34: Risk Management and Recalls
- W-35: The Importance of Measuring TMF Health for Continuous Inspection Readiness